Weiss, Glen J Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. [electronic resource] - Investigational new drugs 02 2018 - 85-95 p. digital Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't ISSN: 1573-0646 Standard No.: 10.1007/s10637-017-0491-7 doi Subjects--Topical Terms: Administration, OralAgedAntineoplastic Agents--administration & dosageCell Cycle Proteins--antagonists & inhibitorsDose-Response Relationship, DrugFemaleHumansMaleMaximum Tolerated DoseMiddle AgedNeoplasms--drug therapyNeutropenia--chemically inducedProtein Kinase Inhibitors--administration & dosageProtein Serine-Threonine Kinases--antagonists & inhibitorsProto-Oncogene Proteins--antagonists & inhibitorsThrombocytopenia--chemically inducedTreatment OutcomePolo-Like Kinase 1